1. Generics Bulletin

Sandoz Partner Samsung Bioepis Settles On Stelara In US

Partners Snag Third-Earliest Launch Date So Far For Biosimilar Ustekinumab

 
• By Dave Wallace

Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.

Handshake, striking a deal, settlement
Samsung Bioepis has settled with J&J • Source: Shutterstock

Samsung Bioepis has announced a settlement with Johnson & Johnson that will allow the Korean firm’s US marketing partner Sandoz to launch the pair’s partnered SB17 biosimilar to Stelara (ustekinumab) from 22 February 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products